Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Matthew A. Powell, David Cibula, David M. O'Malley, Ingrid Boere, Mark S. Shahin, Antonella Savarese, Dana M. Chase, Lucy Gilbert, Destin Black, Jørn Herrstedt, Sudarshan Sharma, Stefan Kommoss, Michael A. Gold, Anna M. Thijs, Kari Ring, Magnus Frödin Bolling, Joseph Buscema, Sarah E. Gill, Paul Nowicki, Nicole Nevadunsky, Michael Callahan, Lyndsay Willmott, Carolyn McCourt, Caroline Billingsley, Sharad A. Ghamande, Zangdong He, Morad Marco Balas, Shadi Stevens, Evelyn Fleming, Mansoor Raza Mirza

Open source

DOI: 10.1016/j.ygyno.2024.10.022
Published: 2025-01
Container: Gynecologic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2024.10.022,
  title = {Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)},
  author = {Matthew A. Powell and David Cibula and David M. O'Malley and Ingrid Boere and Mark S. Shahin and Antonella Savarese and Dana M. Chase and Lucy Gilbert and Destin Black and Jørn Herrstedt and Sudarshan Sharma and Stefan Kommoss and Michael A. Gold and Anna M. Thijs and Kari Ring and Magnus Frödin Bolling and Joseph Buscema and Sarah E. Gill and Paul Nowicki and Nicole Nevadunsky and Michael Callahan and Lyndsay Willmott and Carolyn McCourt and Caroline Billingsley and Sharad A. Ghamande and Zangdong He and Morad Marco Balas and Shadi Stevens and Evelyn Fleming and Mansoor Raza Mirza},
  year = {2025},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2024.10.022},
  url = {https://doi.org/10.1016/j.ygyno.2024.10.022}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
AU  - Matthew A. Powell
AU  - David Cibula
AU  - David M. O'Malley
AU  - Ingrid Boere
AU  - Mark S. Shahin
AU  - Antonella Savarese
AU  - Dana M. Chase
AU  - Lucy Gilbert
AU  - Destin Black
AU  - Jørn Herrstedt
AU  - Sudarshan Sharma
AU  - Stefan Kommoss
AU  - Michael A. Gold
AU  - Anna M. Thijs
AU  - Kari Ring
AU  - Magnus Frödin Bolling
AU  - Joseph Buscema
AU  - Sarah E. Gill
AU  - Paul Nowicki
AU  - Nicole Nevadunsky
AU  - Michael Callahan
AU  - Lyndsay Willmott
AU  - Carolyn McCourt
AU  - Caroline Billingsley
AU  - Sharad A. Ghamande
AU  - Zangdong He
AU  - Morad Marco Balas
AU  - Shadi Stevens
AU  - Evelyn Fleming
AU  - Mansoor Raza Mirza
PY  - 2025
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2024.10.022
UR  - https://doi.org/10.1016/j.ygyno.2024.10.022
ER  -

APA

Powell, M. A., Cibula, D., O'Malley, D. M., Boere, I., Shahin, M. S., Savarese, A., Chase, D. M., Gilbert, L., Black, D., Herrstedt, J., Sharma, S., Kommoss, S., Gold, M. A., Thijs, A. M., Ring, K., Bolling, M. F., Buscema, J., Gill, S. E., Nowicki, P., Nevadunsky, N., Callahan, M., Willmott, L., McCourt, C., Billingsley, C., Ghamande, S. A., He, Z., Balas, M. M., Stevens, S., Fleming, E., & Mirza, M. R. (2025). Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2024.10.022

Source records

crossref · retrieved 2026-09-26T18:54:05.891Z